$7.96
0.669.04%
At Close: -
$7.96
00.00%
After Hours: Jul 19, 4:01 PM EDT
15 minutes delayed
Comments
Loading...
NeuroPace
NPCENASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
NeuroPace (NASDAQ:NPCE) Stock, Analyst Ratings, Price Targets, Forecasts
NeuroPace Inc has a consensus price target of $16.44 based on the ratings of 9 analysts. The high is $26 issued by Baird on August 18, 2021. The low is $8 issued by Morgan Stanley on July 15, 2024. The 3 most-recent analyst ratings were released by Morgan Stanley, Cantor Fitzgerald, and Wells Fargo on July 15, 2024, May 9, 2024, and March 14, 2024, respectively. With an average price target of $15.33 between Morgan Stanley, Cantor Fitzgerald, and Wells Fargo, there's an implied 92.63% upside for NeuroPace Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Cantor Fitzgerald
Wells Fargo
JP Morgan
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for NeuroPace
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/15/2024 | Buy Now | 0.5% | Morgan Stanley | Drew Ranieri | $9.5 → $8 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 126.13% | Cantor Fitzgerald | Ross Osborn | → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 03/14/2024 | Buy Now | 151.26% | Wells Fargo | Lawrence Biegelsen | $16 → $20 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/12/2024 | Buy Now | 113.57% | JP Morgan | Robbie Marcus | $9 → $17 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 126.13% | Cantor Fitzgerald | Ross Osborn | $16 → $18 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 63.32% | Morgan Stanley | Drew Ranieri | $9 → $13 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 101.01% | Wells Fargo | Lawrence Biegelsen | $9 → $16 | Maintains | Equal-Weight | Get Alert |
| 01/30/2024 | Buy Now | 176.38% | Leerink Partners | Mike Kratky | → $22 | Initiates | → Outperform | Get Alert |
| 12/27/2023 | Buy Now | 50.75% | Lake Street | Frank Takkinen | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | Buy Now | 13.07% | Morgan Stanley | Drew Ranieri | $8 → $9 | Maintains | Equal-Weight | Get Alert |
| 11/14/2023 | Buy Now | 0.5% | Morgan Stanley | Drew Ranieri | $6 → $8 | Maintains | Equal-Weight | Get Alert |
| 11/10/2023 | Buy Now | 38.19% | Cantor Fitzgerald | Ross Osborn | → $11 | Initiates | → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 13.07% | JP Morgan | Robbie Marcus | $6 → $9 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | 13.07% | Wells Fargo | Lawrence Biegelsen | $6 → $9 | Maintains | Equal-Weight | Get Alert |
| 08/24/2023 | Buy Now | -24.62% | Morgan Stanley | Drew Ranieri | $5 → $6 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | -37.19% | Morgan Stanley | Drew Ranieri | $4.5 → $5 | Maintains | Underweight | Get Alert |
| 03/03/2023 | Buy Now | -43.47% | Morgan Stanley | Drew Ranieri | $2.5 → $4.5 | Maintains | Underweight | Get Alert |
| 02/22/2023 | Buy Now | 25.63% | Lake Street | Frank Takkinen | → $10 | Initiates | → Buy | Get Alert |
| 01/06/2023 | Buy Now | -68.59% | Morgan Stanley | Drew Ranieri | $3.5 → $2.5 | Maintains | Underweight | Get Alert |
| 10/11/2022 | Buy Now | -56.03% | Morgan Stanley | Drew Ranieri | $5.5 → $3.5 | Maintains | Underweight | Get Alert |
| 07/15/2022 | Buy Now | -30.9% | Morgan Stanley | Drew Ranieri | $6 → $5.5 | Maintains | Underweight | Get Alert |
| 05/13/2022 | Buy Now | -24.62% | Morgan Stanley | Drew Ranieri | $9 → $6 | Maintains | Underweight | Get Alert |
| 05/13/2022 | Buy Now | -24.62% | Wells Fargo | Lawrence Biegelsen | $9 → $6 | Maintains | Equal-Weight | Get Alert |
| 04/06/2022 | Buy Now | 63.32% | Wolfe Research | Mike Polark | → $13 | Initiates | → Outperform | Get Alert |
| 03/11/2022 | Buy Now | 13.07% | Wells Fargo | Lawrence Biegelsen | $11 → $9 | Maintains | Equal-Weight | Get Alert |
| 03/11/2022 | Buy Now | 50.75% | SVB Leerink | Danielle Antalffy | $15 → $12 | Maintains | Outperform | Get Alert |
| 01/19/2022 | Buy Now | 38.19% | Wells Fargo | Lawrence Biegelsen | → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/07/2022 | Buy Now | 50.75% | Morgan Stanley | Drew Ranieri | $17 → $12 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 08/18/2021 | Buy Now | 226.63% | Baird | Mike Polark | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for NeuroPace (NPCE) stock?
The latest price target for NeuroPace (NASDAQ:NPCE) was reported by Morgan Stanley on July 15, 2024. The analyst firm set a price target for $8.00 expecting NPCE to rise to within 12 months (a possible 0.50% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeuroPace (NPCE)?
The latest analyst rating for NeuroPace (NASDAQ:NPCE) was provided by Morgan Stanley, and NeuroPace maintained their equal-weight rating.
When was the last upgrade for NeuroPace (NPCE)?
The last upgrade for NeuroPace Inc happened on March 14, 2024 when Wells Fargo raised their price target to $20. Wells Fargo previously had an equal-weight for NeuroPace Inc.
When was the last downgrade for NeuroPace (NPCE)?
The last downgrade for NeuroPace Inc happened on January 19, 2022 when Wells Fargo changed their price target from N/A to $11 for NeuroPace Inc.
When is the next analyst rating going to be posted or updated for NeuroPace (NPCE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroPace, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroPace was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.
Is the Analyst Rating NeuroPace (NPCE) correct?
While ratings are subjective and will change, the latest NeuroPace (NPCE) rating was a maintained with a price target of $9.50 to $8.00. The current price NeuroPace (NPCE) is trading at is $7.96, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.